Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AASLD 2015: Gilead Leads Race To Shorter, Pan-Genotypic HCV Treatments

This article was originally published in Scrip

Executive Summary

Gilead Sciences has led the race to market with ribavirin- and interferon-free therapies that cure most people with the hepatitis C virus (HCV), but Merck & Co. Inc. is gaining ground in the sprint toward shorter-term, pan-genotypic, two- and three-drug regimens, with AbbVie Inc. on their heels with its own dual therapy that also may eliminate HCV infection in some of the most difficult to treat patients.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC030332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel